

1 **Hi-C detects genomic structural variants in peripheral blood of pediatric leukemia patients**

2
3
4 Claire Mallard^{1,2*}, Michael J Johnston^{1,2*}, Anna Bobyn^{1,2}, Ana Nikolic^{1,2,3}, Bob Argiropoulos^{2,4},
5 Jennifer A Chan^{1,2,5}, Gregory MT Guilcher^{1,2,6§}, Marco Gallo^{1,2,3§}

6
7 ¹Arnie Charbonneau Cancer Institute

8 ²Alberta Children's Hospital Research Institute

9 ³Department of Molecular Biology and Biochemistry

10 ⁴Department of Medical Genetics

11 ⁵Department of Oncology

12 ⁶Department of Pediatrics

13 Cumming School of Medicine, University of Calgary, Calgary, AB

14
15 *Co-first authors

16 §Corresponding authors

17
18
19 Correspondence to: marco.gallo@ucalgary.ca (MG)

20 greg.guilcher@albertahealthservices.ca (GMTG)

52 ABSTRACT

53
54 B-cell acute lymphoblastic leukemia (B-ALL) is often driven by chromosome translocations that
55 result in recurrent and well-studied gene fusions. Currently, fluorescent in-situ hybridization
56 probes are employed to detect candidate translocations in bone marrow samples from B-ALL
57 patients. Recently Hi-C, a sequencing-based technique originally designed to reconstruct the
58 three-dimensional architecture of the nuclear genome, was shown to effectively recognize
59 structural variants. Here, we demonstrate that Hi-C can be used as a genome-wide assay to
60 detect translocations and other structural variants of potential clinical interest. Structural variants
61 were identified in both bone marrow and peripheral blood samples, including an *ETV6-RUNX1*
62 translocation present in one pediatric B-ALL patient. Our report provides proof-of-principle that
63 Hi-C could be an effective strategy to globally detect driver structural variants in B-ALL peripheral
64 blood specimens, reducing the need for invasive bone marrow biopsies and candidate-based
65 clinical tests.

66 67 68 69 INTRODUCTION

70
71 B-cell acute lymphoblastic leukemia (B-ALL) is a malignancy of the bone marrow and blood that
72 results in uncontrolled proliferation of B-cell lineage progenitors. The frequency distribution of B-
73 ALL diagnoses is bimodal, with peaks in childhood and in adults around 50 years of age (reviewed
74 in¹). New treatment approaches have considerably improved overall outcomes in children, with
75 98% of pediatric patients going into remission following treatment and a cure rate of 90%. On the
76 other hand, clinical management of adult B-ALL has proven more challenging, with median overall
77 survival of 11 months.

78
79 At the genomic level, B-ALL is primarily driven by translocations and other structural variants
80 (SVs) that are thought to originate in B-lymphocyte progenitor cells. Some recurrent translocations
81 occur with high frequency in the patient population and can result in tumorigenic, gain-of-function
82 fusion proteins. These genomic events include t(9;22) (a translocation between chromosome 9
83 and chromosome 22, also known as the Philadelphia chromosome) resulting in *BCR-ABL1* fusion;
84 t(12;21), resulting in the *ETV6-RUNX1* fusion; t(1;19), resulting in the *TCF3-PBX1* fusion; and
85 rearrangements of the *MLL* gene with many fusion partners (reviewed in²). Detection of specific
86 translocation(s) and SVs present at diagnosis allows molecular subtyping of the B-ALL case,
87 which informs patient prognosis and guides therapy selection.

88
89 Clinical tests for the detection of translocations mostly rely on fluorescent in-situ hybridization
90 (FISH) of bone marrow samples. Bone marrow cells are obtained via pelvic bone tap, which is an
91 invasive and painful procedure. Since this is a candidate-based clinical test, multiple FISH probes
92 must be used to assay for candidate translocations. Karyotyping is also performed on these
93 samples, but this method may miss SVs that are not big enough to be detected. Being able to
94 capture different types of SVs – including smaller events – in one individual test could improve
95 speed and precision of diagnosis.


96
97 In this report, we test the potential of Hi-C³ – a chromosome conformation capture technique – to
98 provide effective genome-wide information on the SV status of B-ALL samples. Hi-C was originally
99 designed to assess physical interactions between non-contiguous chromosome regions^{4,5}. This
100 information is then used to computationally reconstruct three-dimensional (3D) genome
101 architecture (i.e. how DNA folds within the nucleus). In essence, Hi-C involves crosslinking DNA
102 within cells to create a snapshot of which genomic regions physically interact with each other.

103 When libraries of interacting regions are sequenced very deeply, it is possible to reconstruct both
104 large-scale genomic structures (domains and compartments) and finer features like chromatin
105 loops formed by cis regulatory regions interacting with their target promoters^{4,6}.

106
107 Hi-C can visualize major SVs in a sample⁷. For instance, translocations would appear as
108 interactions between regions normally situated on different chromosomes with a characteristic
109 butterfly appearance on a Hi-C contact map (**Fig 1**). Recent publications have shown that Hi-C
110 enables detection of SVs even with relatively shallow sequencing of the libraries^{7,8}.

111
112 Here, we assess the feasibility of using shallow (low-coverage) Hi-C to infer translocations and
113 other SVs in a discovery cohort of children with B-ALL. We also test the feasibility of detecting
114 SVs by performing Hi-C on peripheral blood of B-ALL patients as a less-invasive alternative to
115 using bone marrow aspirates.

116
117
118
119



120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143

Fig 1. Identification of chromosomal translocations with Hi-C.

(a) Diagram illustrating the expected Hi-C contact frequency maps in the case of a genome with no translocations. A normal karyotype will result in minimal interchromosomal contacts.

(b) Diagram illustrating the expected Hi-C contact frequency maps in the case of a genome a balanced translocation. Elevated interchromosomal contacts would be observed. A balanced translocation would appear as a contact with a characteristic “butterfly” appearance (enlarged inset).

144 **RESULTS**

145
146 **Hi-C datasets of bone marrow and peripheral blood samples from pediatric B-ALL patients**

147 We generated Hi-C libraries for 5 samples from 4 pediatric B-ALL patients (**Table 1**) with an
148 average contact resolution of ~35 kb. For all the relevant statistics related to the Hi-C libraries,
149 please see **Supplemental Table S1**. For patient 4437, we generated Hi-C data on both bone
150 marrow cells (4437M) and peripheral blood cells (4437B) to test our hypothesis that translocations
151 and structural variants can be detected in leukemic blasts that circulate in the peripheral blood.
152 For all the other patients, we generated Hi-C datasets from their peripheral blood. For each
153 patient, we also had clinical data about their B-ALL diagnosis using FISH (**Table 2**). Our cohort
154 included 2 males and 2 females. Samples from 3 patients were collected at initial diagnosis of
155 leukemia. The sample from patient 4441 was obtained when that individual was in remission.

156
157
158






Table 1: Patient metadata.

Patient ID	Diagnosis	Type of Blood Sample Obtained	Sex
4437	B-ALL	marrow and peripheral	Female
4439	B-ALL	peripheral	Male
4440	B-ALL	peripheral	Male
4441	B-ALL	peripheral	Female

159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176

Hi-C maps generated from all samples were informative of the overall genomic structure of all samples (**Fig 2a-e**). They all show strong interactions primarily within each chromosome, as expected, including stronger interactions that preferentially occur within the p-arm and q-arm of each chromosome. However, it is also possible to notice putative interactions between chromosomes, which likely represent SVs. A candidate SV, for instance, appears as a translocation between the q-arm of chromosome 1 and chromosome 9 in patient 4440 (**Fig 2d**).

We uploaded the processed Hi-C maps for all 5 samples to the WashU Epigenome Browser (https://wangftp.wustl.edu/hubs/gallo_B-ALL) to facilitate public access to our datasets and their downstream analyses by users. The raw Hi-C data are also available (see Data Availability section). We hope these datasets will be a resource for the community.



178 **Fig 2. Hi-C contact maps for 5 samples collected from pediatric B-ALL patients.**
179 (a) Contact map for Hi-C data generated from the bone marrow sample of patient 4437.
180 (b) Contact map for Hi-C data generated from the peripheral blood sample of patient 4437.
181 (c) Contact map for Hi-C data generated from the peripheral blood sample of patient 4439.
182 (d) Contact map for Hi-C data generated from the peripheral blood sample of patient 4440.
183 (e) Contact map for Hi-C data generated from the peripheral blood sample of patient 4441.

184
185
186
187


188 **Identification of translocations using Hi-C datasets**

189

190 As a first test of our datasets, we wanted to determine if B-ALL related translocations could be
191 detected using Hi-C data from the bone marrow sample we profiled. Clinical FISH probes
192 confirmed that leukemic blasts from patient 4437 were positive for the *ETV6-RUNX1*
193 translocation, which is a driver mutation for B-ALL and occurs via a balanced exchange of DNA
194 between chromosome 12 and 21. Focusing on these chromosomes, we were able to identify this
195 translocation, which appeared as a butterfly shaped signal, as expected (**Fig 3a**). Furthermore,
196 our datasets allowed identification of the precise breakpoints of the *ETV6-RUNX1* translocation
197 in this patient. The Hi-C contact matrix showed breakpoints corresponding to intron 5 of *ETV6*
198 and intron 2 of *RUNX1* (**Fig 3b**). These results support previous findings on this well-researched
199 translocation.

200

201 Next, for the same patient, we looked for that same translocation using Hi-C data from peripheral
202 blood. Although peripheral blood has lower density of leukemic blasts than the bone marrow, we
203 were still able to identify a significant signal at the expected site of translocation (**Fig 3c**). This
204 finding is further supported by comparing the signals observed in the translocation-positive patient
205 (4437) and a translocation-negative patient (4441). At the *ETV6-RUNX1* intersection locus for
206 patient 4441, there is no significant signal from the peripheral blood Hi-C data (**Fig 3d**). Altogether,
207 our results support the notion that shallow Hi-C has sufficient sensitivity to detect SVs, even in
208 peripheral blood samples from B-ALL patients.



209
210 **Fig 3. The ETV6:RUNX1 translocation detected in bone marrow and peripheral blood Hi-C contact maps**
211 (a) The interchromosomal contact map showing interactions between chr. 12 (0 – 24 Mb) and chr. 21 (22 – 45 Mb) for
212 the bone marrow sample of patient 4437. The bright red butterfly shape shows the balanced translocation at the ETV6
213 locus (chromosome 12) and the RUNX1 locus (chromosome 21)
214 (b) Higher magnification view of the *RUNX1-ETV6* translocation detected by Hi-C in the bone marrow sample of patient
215 4437 (previous panel). The *ETV6* and *RUNX1* genes are shown to illustrate how the data can clearly identify the
216 breakpoint of the translocation. The breakpoint for *ETV6* occurs in intron 5 and the breakpoint for *RUNX1* occurs in
217 intron 2.
218 (c) Interchromosomal contact map showing interactions between chromosome 12 (0 – 24 Mb) and chromosome 21 (22
219 – 45 Mb) for the peripheral blood sample of patient 4437. The bright red butterfly shape shows the balanced
220 translocation at the ETV6 locus (chromosome 12) and the RUNX1 locus (chromosome 21).

221 (d) Interchromosomal contact map for chromosome 12 (0 – 24 Mb) and chromosome 21 (22 – 45 Mb) for the peripheral
222 blood sample of patient 4441. The absence of abnormal signal signifies that no translocation between these loci is
223 present in this sample.

224
225
226

227 **Identification of complex SVs in pediatric B-ALL samples using Hi-C**

228

229 Having established that shallow Hi-C enables the detection of known B-ALL translocations, we
230 then wondered if we could use our datasets to identify other SVs in the genomes of our patients.
231 Examining our datasets, we were able to identify SVs that were not reported following clinical
232 tests for the same patients (**Table 2**). These SVs appeared as strong signals off the diagonal of
233 Hi-C contact matrices. Among the signals identified were candidate tandem duplications,
234 inversions and deletions, but further analyses would be required to fully characterize each SV.
235 However, the detection of abnormalities and the genes involved at these loci are a starting point
236 for further analysis into these cancer genotypes that would not be possible to explore using only
237 clinical FISH probes.

238

239 For patient 4439, complex intrachromosomal structural variants were detected around the *RUNX1*
240 locus on chromosome 21 (**Fig 4a**). Some cytogenic abnormalities were detected near this locus
241 in clinical analysis, but Hi-C was able to specifically identify the breakpoints. It is possible that this
242 SV could affect *RUNX1* expression, but we cannot confirm this hypothesis with the data we
243 currently have. Further, the effects seen line up closely with a known B-ALL cytogenetic subgroup
244 known as iAMP21 - intrachromosomal amplification of chromosome 21⁹. Further, this subgroup
245 has a 3-fold higher relapse rate and a lower 5-year survival (71%) than other B-ALL patients⁹,
246 making the rapid diagnosis and characterization of the leukemia critical for proper diagnosis and
247 clinical management of these high-risk patients.

248

249 Further structural variants were detected in the bone marrow Hi-C contact matrix for sample
250 4437M, in which we previously detected the *ETV6-RUNX1* translocation (**Fig 4b**). These
251 abnormalities were detected as discontinuous, long-range intrachromosomal interactions along
252 chromosome 12 near the *ETV6* locus, suggesting that the local chromatin environment around
253 *ETV6* may be further disrupted independent of the *ETV6-RUNX1* fusion. Further, the breakpoints
254 of another potential SV (lower interaction box in **Fig 4b**) correspond to the genes *APOBEC1* and
255 *LMO3*. Both genes have been identified as important for leukemias in previous studies. *APOBEC1*
256 encodes a cytosine deaminase and has been linked to cancer development in acute myeloid
257 leukemia¹⁰. *LMO3* codes for a transcription factor and oncogene that contributes to the etiology
258 of T-cell acute lymphoblastic leukemia¹¹.


259

260 We also identified a complex SV on the p-arm of chromosome 14 of the sample from patient 4440
261 (**Fig 4c**). This cluster of abnormal Hi-C signals is consistent with a chromothripsis event, in which
262 the chromosome was partially shattered, and many gene loci were altered all at once. This SV
263 was not observed in previously published Hi-C data from a glioblastoma sample (G523)¹², which
264 has non-altered chromosomal structure in this region (upper half of **Fig 4d**).

265 **Table 2. Comparison of structural variants detected by conventional cytogenetic analysis and Hi-C.**

Sample ID	Structural Variants	Detected in clinic?	Detected by Hi-C
4437M	t(12:21) (ETV6:RUNX1)	✓	✓
	intrachromosomal SVs on chr. 12p near ETV6	✗	✓
4437B	t(12:21) (ETV6:RUNX1)	✓	✓
4439	intrachromosomal SVs on chr. 21q near RUNX1	unexplained signal	explained signal
	deletion 21q22.3	✗	✓
4440	intrachromosomal SVs on chr. 14q12	✗	✓
4441			

266
267
268



269
270
271
272
273
274
275
276
277
278
279

Fig 4. Hi-C enables genome-wide identification of structural variants.

(a) Intrachromosomal structural variants near the *RUNX1* locus on chromosome 21 (28 – 42 MB) for patient 4439.
(b) Intrachromosomal structural variants near the *ETV6* locus on chromosome 12 (6 – 18 MB) in the bone marrow sample of patient 4437.
(c) Intrachromosomal structural variants on chromosome 14 (20 – 33 MB) for patient 4440.
(d) Intrachromosomal structural variants on chromosome 14 (20 – 33 MB) for patient 4440 (bottom-left triangle) compared with the same region on a GBM patient Hi-C contact map (top-right triangle).
For all panels, the putative structural variants are highlighted in blue boxes.

280 **3D modeling of B-ALL chromatin interactions**

281
282 In addition to large-scale SVs, Hi-C provides information on chromatin interactions along
283 chromosome regions that do not harbor obvious SVs^{4,5}. 3D chromatin interactions result in the
284 formation of domains and loops, which are important factors for gene expression and
285 determination of cell states¹³. We decided to test whether our shallow Hi-C data were sufficient to
286 probe chromatin interactions in B-ALL patient samples. To achieve this goal, we used CSynth¹⁴,
287 a computational tool that generates 3D models of chromosomes based on data generated from
288 chromosomal conformation techniques like Hi-C. We modelled a region of chromosome 12 (77 –
289 86 MB) and looked for differences in loop structure between bone marrow cells (**Fig 5a**) and
290 peripheral blood cells (**Fig 5b**) for patient 4437. We expected to see differing loop structure
291 between the two, since 3D chromatin looping structures are cell-type specific. We highlighted two
292 pairs of loop anchors corresponding to two loops: 77.1 – 77.8 MB and 78.1 – 79.4 MB (**Fig 5a,b**;
293 green and red, respectively). In Hi-C, the intensity of the loops was higher in the bone marrow
294 data, likely due to the different density of bone-marrow specific cells, such as B-lymphocytes. This
295 was supported by the 3D models which showed tighter and more distinct loops in the bone marrow
296 model than in the peripheral blood model, as seen by the closer proximity of the green and red
297 loop boundaries.

298
299 Next, we wanted to see if this phenomenon would be apparent for specific enhancer to gene loops
300 related to leukemias. We identified putative cis regulatory regions using chromatin
301 immunoprecipitation with sequencing (ChIP-seq) data for B cells and for GM12878, a
302 lymphoblastoid cell line, generated by ENCODE¹⁵. Specifically, we looked at acetylation of histone
303 3 on lysine 27 (H3K27ac), which marks enhancer and promoter regions. We found a strong loop
304 present from the bone marrow Hi-C between a putative enhancer marked by H3K27ac and the
305 proto-oncogene *MYB* which is over-expressed in leukemias¹⁶. In the Hi-C contact matrix for
306 patient 4437 bone marrow, there was a strong signal at the interaction locus for the enhancer and
307 *MYB* (**Fig 5c**). This corresponded to an obvious loop structure in the 3D model (**Fig 5c**). In the
308 peripheral blood Hi-C contact matrix for the same patient, there was a signal present, but with
309 lower intensity. The 3D model also showed the loop, but the boundaries were farther apart (**Fig**
310 **5d**). Finally, this loop was not present in the Hi-C contact matrix of a previously published
311 glioblastoma sample (**Fig 5e**). These results demonstrate that shallow Hi-C datasets of clinical
312 samples are sufficient to reconstruct the 3D milieu of specific genomic regions that are relevant
313 to disease etiology.

314




Fig 5. 3D modeling of shallow Hi-C data reveals information on gene regulation.

(a-b) Hi-C based 3D models of chromosome 12 (77 – 86 MB) from patient 4437 displaying both bone marrow (a) or peripheral blood (b). Green highlights the loop boundaries for the loop spanning 77.1 – 77.8 MB and red highlights the loop boundaries for the loop spanning 78.1 – 79.4 MB.

(c-e) Hi-C contact matrices and 3D models of chromosome 6: 134.7 – 135.7 MB for patient 4437 bone marrow (c) patient 4437 peripheral blood (d) and a control glioblastoma patient (e). The loop formed between an H3K27ac enhancer region and the gene MYB is highlighted in the blue box on the Hi-C matrix and by red loop boundaries in the 3D model. ChIP-seq tracks for the histone mark H3K27ac for a primary B cell sample and a cell line (GM12878) are shown in each panel.

315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332

333 DISCUSSION

334
335 Hi-C has been shown to be an effective genomic approach to solve the 3D architecture of the
336 genome, and also to identify large SVs^{7,8}. We reasoned that the unbiased, genome-wide
337 assessment of structural variation offered by Hi-C could be an asset in the diagnosis and
338 molecular subtyping of malignancies driven by defined SVs, especially translocations. We
339 therefore decided to focus our efforts on B-ALL, which is very often driven by translocation events
340 that generate gene fusions that maintain malignant cells in progenitor states.

341
342 Balanced translocations can easily be visualized in Hi-C contact maps by virtue of their
343 characteristic “butterfly” shape. One of our patients had a canonical translocation between
344 chromosomes 12 and 21, resulting in the *ETV6-RUNX1* gene fusion. This translocation was
345 confirmed by FISH. Our shallow Hi-C approach was able to clearly identify this translocation in
346 the bone marrow sample by simple visual inspection. Importantly, we were also able to detect this
347 translocation in the peripheral blood sample from the same patient. Additionally, we successfully
348 identified other putative SVs in the peripheral blood samples of other 2 patients. The blood sample
349 from an additional patient was collected when the child was in remission and, as expected, did
350 not have obvious abnormal Hi-C signals. Overall, our data support the suitability of shallow Hi-C
351 as a tool to detect known and unknown SVs in B-ALL genomes.

352
353 Although we only had one patient-matched pair of bone marrow and peripheral blood specimens,
354 our results provide proof-of-principle that shallow Hi-C can be successfully applied to peripheral
355 blood samples to detect recurrent translocations in B-ALL patients. The success of this approach
356 depends upon on the burden of leukemic blasts in circulation and could correlate with disease
357 stage. We expect that simple refinements of the approach we describe could significantly improve
358 the power to detect translocations using peripheral blood. For instance, a simple solution would
359 be to enrich for leukemic blasts by performing fluorescence-activated cell sorting directly on
360 peripheral blood^{17,18}. This approach would reduce the need for bone marrow biopsies, which can
361 be painful procedures.

362
363 In patients who did not have the recurrent *ETV6-RUNX1* translocation, we also detected putative
364 SVs near *ETV6* and *RUNX1*. This finding is interesting, because it suggests that there may be
365 alternative mechanisms of disrupting proper expression of these genes in addition to the
366 canonical translocation. Hi-C allows the visualization of large genomic abnormalities and could
367 provide information of the potential disruption of transcriptional programs associated with these
368 genes. Leukemias that converge on disruption of transcriptional pathways mediated by *ETV6* and
369 *RUNX1*, whether through translocations or other means, could be identified.

370
371 In addition to providing unbiased, genome-wide contact data, Hi-C may also be more cost-
372 effective than clinical FISH probes. To detect SVs, Hi-C can be performed at low resolution for a
373 cost of \$200-\$1000 per sample (range depends on desired resolution and sequencing
374 instruments available), offering cost effectiveness and improved sensitivity for unanticipated
375 genomic events. Therefore shallow Hi-C is cost-competitive with other sequencing-based
376 methods that are currently in use for diagnosis and molecular subtyping of leukemias in some
377 hospitals¹⁹.

378
379 Shallow Hi-C does have some limitations. These include the specialized informatic analysis
380 required and its inability to detect very small SVs (e.g. single-gene duplications or very small
381 deletions). Hi-C output is also relatively qualitative, and visual inspection is required for inferences
382 of genomic structural anomalies. However, future studies could lead to standard computational
383 pipelines for accurate identification of SVs using Hi-C.

384
385 Additional studies with larger cohorts of patients will be required, but our results suggest that
386 shallow Hi-C could be used to reinforce standard of care testing (flow cytometry and cytogenetics)
387 and hopefully implemented in the clinic to test for translocations using peripheral blood of B-ALL
388 samples. The standardization of Hi-C library preparation and its related computational pipelines,
389 and wide availability of sequencing in clinical settings, make this option worth exploring.

390 391 **METHODS**

392 **Patient samples**

393
394 Collection of all samples was based on written informed consent and their use was approved by
395 the Health Research Ethics Board of Alberta Cancer Committee (certificate number HREBA.CC-
396 18-0169).

397 **Generation of Hi-C datasets**

398
399 Peripheral or marrow blood samples were collected from patients with B-ALL at the Alberta
400 Children's Hospital. Blood samples were diluted 1:1 with PBS + 2% FBS. Peripheral blood
401 mononuclear cells were isolated using SepMate columns (Stemcell Technologies). Cells were
402 rinsed and resuspended to 25 mL in PBS + 2% FBS. Cell density was measured using a Countess
403 cell counter (ThermoFisher). One to five million cells were then used as input for Hi-C library
404 construction using the Arima Hi-C Kit (Arima Genomics), including KAPA Hyper Prep indexing
405 and library amplification.

406
407
408 Samples were sequenced 2x150bp on a NextSeq 500 instrument (Illumina) at the Center for
409 Health Genomics and Informatics (CHGI) at the University of Calgary. Reads were processed
410 using Juicer²⁰, aligning to reference genome hg38 and the restriction enzyme DpnII, to generate
411 Hi-C contact matrices (.hic files). Contact matrices were visualised using Juicebox²¹.

412 **SV detection**

413
414 We considered that genomic structural variants would appear as long-range interactions on a Hi-
415 C contact map. Using Juicebox, we visually inspected the whole genome contact map using
416 balanced normalization at 100-kbp resolution for abnormally high interchromosomal signals
417 located >5 Mbp apart. 50-kbp resolution was used to inspect abnormal intrachromosomal signals.
418 Additionally, putative SV signals were inspected to ensure the Observed/Expected ratios were
419 much greater than 1. Finally, putative SV signals were compared to negative control Hi-C datasets
420 in which leukemic disease had cleared (sample 4441) or which would not be expected to share
421 leukemic genomic alterations (published glioblastoma dataset from sample G523¹²).

422 **3D modeling of Hi-C data**

423
424 Hi-C contact matrices and BED files containing loop loci of interest were loaded into CSynth¹⁴
425 (csynth.org). Default parameters were used, with the following exceptions: Push apart force: 3e-
426 4; contact force: 52; diameter: 20.

427 **H3K27ac ChIP-seq datasets**

428
429 We accessed H3K27ac fold enrichment traces from ENCODE¹⁵ through Juicebox with the
430 following identifiers: ENCFF696PMM (Homo sapiens B cell female adult (27 years of age), web
431 link: <https://www.encodeproject.org/files/ENCFF696PMM/>); ENCFF340JIF (Homo sapiens
432 GM12878, web link <https://www.encodeproject.org/files/ENCFF340JIF/>).

435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485

DATA AVAILABILITY

All Hi-C datasets generated for this study are available to the community. The processed Hi-C data can be loaded into the WashU Epigenome Browser from the following link: https://wangftp.wustl.edu/hubs/gallo_B-ALL. The raw Hi-C data have been uploaded at the EGA repository (accession number EGAS00001005605).

AUTHOR CONTRIBUTIONS

MG and GMTG conceived the study. GMTG and JAC collected and banked the patient specimens. CM, MJJ, AB and BA performed the experimental activities. MG, CM and MJJ wrote the manuscript. All co-authors contributed to editing the manuscript.

ACKNOWLEDGMENTS

This project was funded by a Young Investigator Award in Cell and Gene Therapy for Cancer grant from the Alliance for Cancer Gene Therapy (ACGT) to MG; a Discovery Grant from the Natural Science and Engineering Research Council (NSERC) to MG; a Canada Research Chair from the Government of Canada to MG; a USRA studentship from NSERC to CM; a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR) to MJJ; support from the Alberta Children's Hospital Foundation and the Kids Cancer Care Foundation of Alberta to JAC for the Brain Tumor and Tissue Bank.

COMPETING INTERESTS STATEMENT

The authors declare that there are no competing interests.

REFERENCES

1. Terwilliger, T. & Abdul-Hay, M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. *Blood Cancer J.* **7**, e577 (2017).
2. Woo, J. S., Alberti, M. O. & Tirado, C. A. Childhood B-acute lymphoblastic leukemia: a genetic update. *Exp. Hematol. Oncol.* **3**, 16 (2014).
3. Belton, J.-M. *et al.* Hi-C: a comprehensive technique to capture the conformation of genomes. *Methods* **58**, 268–76 (2012).
4. Rao, S. S. P. *et al.* A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* **159**, 1665–1680 (2014).
5. Dixon, J. R. *et al.* Topological domains in mammalian genomes identified by analysis of chromatin interactions. *Nature* **485**, 376–380 (2012).
6. Lu, L. *et al.* Robust Hi-C Maps of Enhancer-Promoter Interactions Reveal the Function of Non-coding Genome in Neural Development and Diseases. *Mol. Cell* **79**, 521-534.e15 (2020).
7. Dixon, J. R. *et al.* Integrative detection and analysis of structural variation in cancer genomes. *Nat. Genet.* **50**, 1388–1398 (2018).
8. Harewood, L. *et al.* Hi-C as a tool for precise detection and characterisation of

- 486 chromosomal rearrangements and copy number variation in human tumours. *Genome*
487 *Biol.* **18**, 125 (2017).
- 488 9. Harrison, C. J. Blood Spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-
489 risk pediatric disease. *Blood* **125**, 1383–6 (2015).
- 490 10. Saraconi, G., Severi, F., Sala, C., Mattiuz, G. & Conticello, S. G. The RNA editing
491 enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is
492 present in esophageal adenocarcinomas. *Genome Biol.* **15**, 417 (2014).
- 493 11. La Starza, R. *et al.* Design of a Comprehensive Fluorescence in Situ Hybridization Assay
494 for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. *J. Mol. Diagn.* **22**,
495 629–639 (2020).
- 496 12. Johnston, M. J. *et al.* High-resolution structural genomics reveals new therapeutic
497 vulnerabilities in glioblastoma. *Genome Res.* **29**, 1211–1222 (2019).
- 498 13. Dixon, J. R. *et al.* Chromatin architecture reorganization during stem cell differentiation.
499 *Nature* **518**, 331–336 (2015).
- 500 14. Todd, S. *et al.* CSynth: an interactive modelling and visualization tool for 3D chromatin
501 structure. *Bioinformatics* **37**, 951–955 (2021).
- 502 15. Davis, C. A. *et al.* The Encyclopedia of DNA elements (ENCODE): data portal update.
503 *Nucleic Acids Res.* **46**, D794–D801 (2018).
- 504 16. Lahortiga, I. *et al.* Duplication of the MYB oncogene in T cell acute lymphoblastic
505 leukemia. *Nat. Genet.* **39**, 593–5 (2007).
- 506 17. Cheng, J., Klairmont, M. M. & Choi, J. K. Peripheral blood flow cytometry for the
507 diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions. *Pediatr. Blood*
508 *Cancer* **66**, e27453 (2019).
- 509 18. Rezaei, A., Adib, M., Mokarian, F., Tebianian, M. & Nassiri, R. Leukemia markers
510 expression of peripheral blood vs bone marrow blasts using flow cytometry. *Med. Sci.*
511 *Monit.* **9**, CR359-62 (2003).
- 512 19. Inaba, H., Azzato, E. M. & Mullighan, C. G. Integration of Next-Generation Sequencing to
513 Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children’s
514 Research Hospital Approach. *Front. Pediatr.* **5**, 258 (2017).
- 515 20. Durand, N. C. *et al.* Juicer Provides a One-Click System for Analyzing Loop-Resolution
516 Hi-C Experiments. *Cell Syst.* **3**, 95–98 (2016).
- 517 21. Durand, N. C. *et al.* Juicebox Provides a Visualization System for Hi-C Contact Maps with
518 Unlimited Zoom. *Cell Syst.* **3**, 99–101 (2016).
- 519
520
521
522
523
524